Cargando…

Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer

BACKGROUND: A dual blockade against the novel immune checkpoint inhibitor lymphocyte activation gene-3 (LAG-3) and programmed cell death protein-1 (PD-1) is currently considered in advanced breast cancer. Nevertheless, PD-1 or LAG-3 expression within distant metastatic breast cancer tissue remains u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sobottka, Bettina, Moch, Holger, Varga, Zsuzsanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792100/ https://www.ncbi.nlm.nih.gov/pubmed/33413541 http://dx.doi.org/10.1186/s13058-020-01380-w

Ejemplares similares

Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases
por: Sobottka, Bettina, et al.
Publicado: (2016)

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Correction: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features
por: Rechsteiner, Markus, et al.
Publicado: (2018)

Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers
por: Kaur, Jaspreet, et al.
Publicado: (2022)

CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer
por: Tallón de Lara, Paulino, et al.
Publicado: (2021)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification
por: Varga, Zsuzsanna, et al.
Publicado: (2014)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
por: Zhong, Yu-Min, et al.
Publicado: (2022)

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers
por: Kaur, Jaspreet, et al.
Publicado: (2023)

Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
por: Stefanovic, Stefan, et al.
Publicado: (2017)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020)

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers
por: Bottai, Giulia, et al.
Publicado: (2016)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3
por: Wu, Shafei, et al.
Publicado: (2021)

The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer
por: Teleki, Ivett, et al.
Publicado: (2013)

Site-specific metabolic phenotypes in metastatic breast cancer
por: Kim, Hye Min, et al.
Publicado: (2014)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

The expression of PD-L1 in salivary gland carcinomas
por: Vital, Domenic, et al.
Publicado: (2019)

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
por: Mollavelioglu, Baran, et al.
Publicado: (2022)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
por: Wei, Yiming, et al.
Publicado: (2022)

Clustered LAG-1 binding sites in lag-1/CSL are involved in regulating lag-1 expression during lin-12/Notch-dependent cell-fate specification
por: Choi, Vit Na, et al.
Publicado: (2013)

Next Generation Sequencing of Reactive Stroma and Residual Breast Cancer Cells in Tumor Bed after Neoadjuvant Chemotherapy
por: Varga, Zsuzsanna, et al.
Publicado: (2022)

The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function
por: Balasko, Allison L., et al.
Publicado: (2023)

PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival
por: Jimenez, Oscar, et al.
Publicado: (2022)

Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers
por: Fischer, Jana Raja, et al.
Publicado: (2023)

LAG-3 expression in tumor microenvironment of triple-negative breast cancer
por: TAHTACI, Gözde, et al.
Publicado: (2022)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

Different Expression Characteristics of LAG3 and PD-1 in Sepsis and Their Synergistic Effect on T Cell Exhaustion: A New Strategy for Immune Checkpoint Blockade
por: Niu, Bailin, et al.
Publicado: (2019)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
por: Mimura, Kosaku, et al.
Publicado: (2021)

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
por: Brignone, Chrystelle, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_sptlpc2brtcfjucl1a3u5sp005